New Data Support OrbusNeich's Combo Dual Therapy Stent

September 18, 2014—OrbusNeich announced 2-year optical coherence tomography (OCT) findings and 3-year clinical follow up from the EGO COMBO study, providing further evidence to support the healing benefits of the OrbusNeich Combo Dual Therapy drug-eluting stent (DES) with the company’s active endothelial progenitor cell (EPC) capture technology.

Prof. Stephen W.L. Lee, MD, of the Queen Mary Hospital in Hong Kong, presented the findings during the Transcatheter Cardiovascular Therapeutics 2014 scientific symposium in Washington, DC.

In the Stentys press release, Prof. Lee commented, “This is the first study to assess the healing profile of a dual therapy stent by OCT. The Combo stent’s unique approach shows early healing benefits and stability over the long-term. The results demonstrate no neoatherosclerosis observed by OCT at 24 months, and no late restenosis or stent thrombosis beyond 36 months. The Combo stent is the only DES that exhibits neointima regression from 9 months to 24 months. This is an indication of true vessel healing.”

Also at TCT, Prof. Michael Haude, MD, presented the latest evidence surrounding the Combo stent’s active EPC capture. The data demonstrated how the Combo stent uses a bound antibody to capture EPCs and promotes accelerated endothelial coverage. Prof. Haude is from Lukaskrankenhaus in Neuss, Germany. Dr. Haude commented in the company’s announcement, “The Combo stent sets a new standard for stenting. With the dual therapy approach of the Combo stent, the abluminal sirolimus release from a bioresorbable polymer matrix controls the restenosis and neointimal proliferation, whilst the luminal surface is coated with an antibody that enables an earlier and more mature healing of the stented lesion. Delayed healing is of continued concern in conventional DES today as it leads to stent thrombosis and, in the long-term, to neoatherosclerosis. The Combo stent helps to address these concerns and may offer a long-term solution.”